Form 4 Filing for Srivastava Sapna at Aura Biosciences, Inc.

On June 11, 2026, Srivastava Sapna, a director at Aura Biosciences, Inc. (AURA), acquired 15,000 shares of Common Stock and was granted 30,000 stock options. The Common Stock acquisition was part of a restricted stock unit (RSU) award under the company's 2021 Stock Option and Incentive Plan, with full vesting expected on June 11, 2027, or the next annual stockholder meeting, contingent upon continued service. The stock options, also vesting under the same conditions, have an exercise price of $6.21 and an expiration date of June 11, 2036. These transactions are reported as direct acquisitions, increasing Sapna's post-transaction holdings to 38,500 shares of Common Stock and 30,000 exercisable stock options.